- Home
- INAB vs CDIO Comparison
INAB vs CDIO Comparison
Compare INAB & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- CDIO
- Stock Information
- Founded
- INAB 2016
- CDIO 2017
- Country
- INAB United States
- CDIO United States
- Employees
- INAB N/A
- CDIO N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- INAB Health Care
- CDIO Health Care
- Exchange
- INAB Nasdaq
- CDIO Nasdaq
- Market Cap
- INAB 14.5M
- CDIO 19.5M
- IPO Year
- INAB 2021
- CDIO N/A
- Fundamental
- Price
- INAB $0.16
- CDIO $0.19
- Analyst Decision
- INAB Strong Buy
- CDIO Buy
- Analyst Count
- INAB 2
- CDIO 1
- Target Price
- INAB $3.60
- CDIO $2.00
- AVG Volume (30 Days)
- INAB 609.1K
- CDIO 1.2M
- Earning Date
- INAB 05-07-2025
- CDIO 05-23-2025
- Dividend Yield
- INAB N/A
- CDIO N/A
- EPS Growth
- INAB N/A
- CDIO N/A
- EPS
- INAB N/A
- CDIO N/A
- Revenue
- INAB N/A
- CDIO $34,890.00
- Revenue This Year
- INAB N/A
- CDIO $1,434.82
- Revenue Next Year
- INAB N/A
- CDIO $4,661.91
- P/E Ratio
- INAB N/A
- CDIO N/A
- Revenue Growth
- INAB N/A
- CDIO 104.45
- 52 Week Low
- INAB $0.13
- CDIO $0.19
- 52 Week High
- INAB $1.74
- CDIO $1.77
- Technical
- Relative Strength Index (RSI)
- INAB 36.75
- CDIO 30.27
- Support Level
- INAB $0.15
- CDIO $0.39
- Resistance Level
- INAB $0.17
- CDIO $0.48
- Average True Range (ATR)
- INAB 0.01
- CDIO 0.06
- MACD
- INAB 0.00
- CDIO -0.02
- Stochastic Oscillator
- INAB 3.17
- CDIO 1.27
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.